Healthcare & Biotech Hedge Funds see asset surge 12%; Glenview Capital, OrbiMed & Visium lead gainers
|August 13th, 2014||
|The most recent Top 50 Healthcare, Pharmaceutical and Biotechnology Focused Hedge Fund list has been released, revealing that the top hedge funds now manage $78 billion in U.S. equity assets, having seen their asset jump by 12% year-to-date.|
Leading the equity asset surge are Glenview Capital (+$1.9B), OrbiMed Advisrs (+$1.1B), Visium Asset Management (+$752M) and Partner Fund Management (+$650M). An impressive 76% of the hedge funds on the list have seen their equity assets increase year-to-date.
Larry Robbins’ Glenview Capital Management has retained the top spot, once again, with $15.1 billion in equity assets under management. Glenview Capital’s sector favorites include Thermo Fisher Scientific (TMO), HCA Holdings Inc (HCA) and Tenet Healthcare Corp (THC). Over the quarter, Glenview Capital significantly increased its bets on Thermo Fisher Scientific, Humana Inc (HUM), and Community Health Systems Inc (CYH).
Other top investors that lead the Top Healthcare, Pharma and Biotech Hedge Fund List include #2 OrbiMed Advisors and #3 PointState Capital. The largest investments for OrbiMed Advisors, which is run by Samuel Isaly, include Intercept Inc (ICPT), Gilead Sciences Inc (GILD), Biogen Idec Inc (BIIB) and Bristol-Myers Squibb (BMY). Over the quarter, Isaly’s firm entered and bought up large stakes in Eli Lilly & Co (LLY), Tornier N.V. (TRNX) and Tesaro, Inc. (TSRO). OribMed also significantly increased its exposure to Intercept Inc (ICPT) and Allergan Inc (AGN) over the quarter.
Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms’ overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker’s Hedge Fund Portal.
For Detailed Investor Profiles on these Investors, click below: